Cereno Scientifics The goal is to develop innovative treatments for cardiovascular disease with better disease-modifying effects and fewer side effects – compared to current options – for patients suffering from both common and rare cardiovascular diseases. In addition to the promising CS585candidate, Cereno's pipeline includes two HDACi (histone deacetylase inhibitors) that act as epigenetic modulators; CS1 in phase II development for pulmonary arterial hypertension (PAH) and CS014 which is currently in preclinical development.
One of the characteristic pathogenic mechanisms of cardiovascular disease is thrombosis – the formation of occlusive blood clots that cut off the blood supply to part or all of an organ, such as the heart or brain, leading to heart attack or stroke, respectively. Today's thrombosis treatments (warfarin, Heparin, platelet inhibitors or NOAC) are relatively good at preventing occlusive clots (thrombosis), but they carry a significant risk of bleeding, which in itself can be life-threatening.
Encouraging preclinical data
The Gothenburg-based biotech company, which is in the clinical stage, has assembled a broad pipeline of drug candidates with the potential to prevent blood clots, with little or no risk of bleeding. One of these candidates is CS585, a stable, selective and potent prostacyclin receptor agonist. When activated, the prostacyclin receptor prevents platelet aggregation in arteries and veins after an injury. By targeting the prostacyclin receptor, CS585 is therefore a strong contender to prevent serious damage in the clinic in the event of an occlusive thrombotic event.
In June, Cereno's Director of Translational Research, Dr. Michael Holinstat, preclinical data related to CS585 at the European Hematology Association (AND HAS) 2022 Hybrid Congress. The data suggest that CS585 not only has the ability to prevent blood clot formation, but can do so without significantly increasing the risk of bleeding. If these results are replicated in the clinic, they would represent a significant breakthrough in the treatment of many cardiovascular diseases in which blood clots form.
Informing the medical community about the benefits of CS585
Being selected to present at EHA is considered a prestigious opportunity within the scientific and medical community, as only a few abstracts are handpicked by a committee of experts in the field.
Following positive feedback from the EHA, Cereno has decided to take further steps to engage and be active within the medical community regarding the company’s preclinical assets, which is a key factor for long-term success. This week, the company published a video in which Dr. Holinstat explains the mechanism of action of CS585 and why it has such high potential in CVD indications. Watch the video below.
In case you missed it, watch Cereno Scientific's short video presentation: from the ground up to the execution of the vision to transform the CVD treatment landscape > https://youtu.be/hdXyJY33JA0
